Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 1 completed trials

    Completion Rate
    100%(1/1)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 2
    2
    100%

    Phase Distribution

    0

    Early Stage

    2

    Mid Stage

    0

    Late Stage

    Phase Distribution2 total trials
    Phase 2Efficacy & side effects
    2(100.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Completed(1)
    Terminated(1)

    Detailed Status

    Completed1
    Withdrawn1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 22 (100.0%)

    Trials by Status

    completed150%
    withdrawn150%

    Recent Activity

    0 active trials
    Showing 2 of 2
    completedphase_2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

    NCT02847559
    withdrawnphase_2

    NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

    NCT02348255

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT02847559Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

    Completed
    NCT02348255Phase 2

    NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

    Withdrawn

    All 2 trials loaded

    Drug Details

    Intervention Type
    Procedure
    Total Trials
    2